Twist Bioscience Intrinsic Value – TWIST BIOSCIENCE Reports Third Quarter FY2023 Earnings Results

🌥️Earnings Overview

On August 4 2023, TWIST BIOSCIENCE ($NASDAQ:TWST) reported its financial results for the third quarter of FY2023, ending June 30 2023. Revenue for the quarter totaled USD 63.7 million, an increase of 13.6% compared to the same quarter of the prior year. However, the company posted a net loss of USD 57.4 million, a decrease of 5.1 million from the prior year quarter.

Price History

This surge in the stock price is largely attributed to TWIST BIOSCIENCE‘s strong quarterly performance, as they have continually been able to expand their reach in the biotechnology industry. This was attributed to record sales of its sequencing and synthetic biology products, as well as increased support for its customers’ research efforts. This is evidenced by the surge in stock price and strong revenue growth, both of which are indicators of the company’s success and potential future growth. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Twist Bioscience. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Twist Bioscience. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Twist Bioscience. More…

Key Ratios Snapshot

Some of the financial key ratios for Twist Bioscience are shown below. More…

Analysis – Twist Bioscience Intrinsic Value

At GoodWhale, we have conducted an analysis of TWIST BIOSCIENCE‘s financials. After extensive research, we have concluded that the intrinsic value of TWIST BIOSCIENCE share is around $106.9. This estimation was calculated through our proprietary Valuation Line, which takes into account the company’s financial performance metrics and market dynamics. Currently, TWIST BIOSCIENCE stock is traded at $23.0, indicating that it is undervalued by 78.5%. We believe that this presents a great opportunity for investors to capitalize on the current market conditions and purchase the stock while it is still undervalued. More…

Peers

It offers DNA synthesis on a silicon chip, which enables the company to offer its services at a lower cost than its competitors. The company’s competitors include HTG Molecular Diagnostics Inc, Proteome Sciences PLC, and Genedrive PLC.

– HTG Molecular Diagnostics Inc ($NASDAQ:HTGM)

FoundHTG’s cutting-edge molecular diagnostic platform and cancer test portfolio offers clinicians actionable insights to improve patient outcomes. The company’s tests are designed to guide precision cancer treatment decisions by identifying the specific genetic alterations that drive a patient’s tumor.

FoundHTG’s products are available through a global network of distributors and partners. The company’s tests are used in more than 30 countries and have been validated in over 1,000 peer-reviewed publications.

FoundHTG has a market cap of $6.07M and a ROE of -156.17%.

– Proteome Sciences PLC ($LSE:PRM)

Proteome Sciences PLC is a United Kingdom-based company, which is engaged in the business of proteomics. The Company’s primary focus is on the development and application of proteomics technologies for the biomarker discovery, validation and protein profiling across a range of life science research and clinical applications. It operates through two segments: Biomarkers and Protein Analysis. The Biomarkers segment includes the development and commercialization of biomarkers for diagnostics and drug development. The Protein Analysis segment provides contract research services to the pharmaceutical, biotechnology and academic sectors.

– Genedrive PLC ($LSE:GDR)

Genedrive PLC is a molecular diagnostics company. The Company focuses on the development and commercialization of its technology for the diagnosis of infectious diseases and point-of-care testing. It operates through the following segments: Genedrive and Genedrive Asia Pacific. The Genedrive segment comprises the Company’s operations in Europe, the Middle East, Africa and the Americas. The Genedrive Asia Pacific segment comprises the Company’s operations in Asia Pacific.

Summary

Investors in TWIST BIOSCIENCE have reason to be optimistic. The company reported quarterly earnings on August 4 2023, with total revenue increasing by 13.6% over the same quarter last year and net income decreasing by 5.1 million from the same quarter last year. This was reflected in the stock price, which moved up on the day of the announcement. Going forward, investors should continue to monitor TWIST BIOSCIENCE’s performance to ensure that their investments remain secure.

Additionally, careful study of market trends and the company’s financials may allow for more successful investing in the future.